First Tracks Biotherapeutics Reports $33.4 Million Net Loss in Q2 2026, Decreased from Previous Year

First Tracks Biotherapeutics, Inc. reported a net loss of $33.4 million for the second quarter of 2026, a decrease from a net loss of $42.4 million in the same period of the previous year. For the first half of 2026, the company recorded a net loss of $83.9 million, compared to a loss of $89.6 million in the first half of 2025. The reduction in losses is attributed to a significant decrease in research and development expenses, which fell to $25.6 million in Q2 2026 from $39.3 million in Q2 2025, and to $59.6 million for the first half of 2026, down from $80.7 million in the prior year. This decline was primarily driven by reduced clinical and related expenses.

The company’s total operating expenses for the second quarter of 2026 were $34.9 million, down from $45.9 million in the same quarter of 2025. General and administrative expenses increased to $9.3 million in Q2 2026 from $6.6 million in Q2 2025, largely due to higher personnel costs and legal expenses. As of June 30, 2026, First Tracks Biotherapeutics had cash and cash equivalents of $168.0 million, a decrease from $238.2 million at the end of 2025, reflecting the company's ongoing investment in its clinical programs.

In terms of strategic developments, First Tracks Biotherapeutics completed its spin-off from AnaptysBio on April 20, 2026, which involved the distribution of approximately 29.1 million shares of common stock to AnaptysBio shareholders. Following the spin-off, the company raised approximately $80 million through a private placement of common stock, which is expected to support its ongoing clinical trials and operational needs. The company is advancing several product candidates, including ANB033 for celiac disease and eosinophilic esophagitis, and rosnilimab for rheumatoid arthritis, with ongoing clinical trials aimed at assessing their safety and efficacy.

Operationally, First Tracks Biotherapeutics is focused on expanding its clinical pipeline and enhancing its market presence. The company is currently conducting a Phase 1b trial for ANB033 in celiac disease and eosinophilic esophagitis, and it has reported positive results from earlier trials for its other candidates. The company anticipates that its existing cash reserves will be sufficient to fund operations for at least the next 12 months, although it may seek additional financing to support its growth and development initiatives. The outlook remains cautiously optimistic as the company navigates the complexities of clinical development and market entry for its therapeutic candidates.